Cargando…

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer

PURPOSE: This study aimed to investigate the feasibility of biomarkers based on dynamic circulating tumor DNA (ctDNA) to classify small cell lung cancer (SCLC) into different subtypes. MATERIALS AND METHODS: Tumor and longitudinal plasma ctDNA samples were analyzed by next-generation sequencing of 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yu, Liu, Yutao, Yuan, Mingming, Dong, Guilan, Zhang, Hongxia, Zhang, Tongmei, Chang, Lianpeng, Xia, Xuefeng, Li, Lifeng, Zhu, Haohua, Xing, Puyuan, Wang, Hongyu, Shi, Yuankai, Wang, Zhijie, Hu, Xingsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296939/ https://www.ncbi.nlm.nih.gov/pubmed/34645133 http://dx.doi.org/10.4143/crt.2021.905

Ejemplares similares

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
por: Liu, Yutao, et al.
Publicado: (2020)

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
por: Feng, Yu, et al.
Publicado: (2022)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
por: Yang, Guangjian, et al.
Publicado: (2022)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
por: Zhang, Yongliang, et al.
Publicado: (2021)

Author Correction: Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
por: Zhang, Yongliang, et al.
Publicado: (2021)

Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2020)

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
por: Han, Xiaohong, et al.
Publicado: (2019)

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China
por: Qi, Fei, et al.
Publicado: (2019)

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis
por: Ma, Di, et al.
Publicado: (2017)

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse
por: Xu, Fei, et al.
Publicado: (2023)

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study
por: Xing, Puyuan, et al.
Publicado: (2022)

Integrated epigenetic biomarkers in circulating cell-free DNA as a robust classifier for pancreatic cancer
por: Cao, Feng, et al.
Publicado: (2020)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Meta-optic accelerators for object classifiers
por: Zheng, Hanyu, et al.
Publicado: (2022)

Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer
por: Wang, Ying, et al.
Publicado: (2023)

A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy
por: Liu, Yutao, et al.
Publicado: (2020)

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population()()
por: Han, Xiaohong, et al.
Publicado: (2014)

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
por: Mu, Yuxin, et al.
Publicado: (2020)

Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer
por: Zhou, Jiaolin, et al.
Publicado: (2016)

Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients
por: Hu, Mingming, et al.
Publicado: (2022)

Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients
por: Zhao, Cong, et al.
Publicado: (2022)

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
por: Wang, Shouzheng, et al.
Publicado: (2021)

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
por: Chen, Dongna, et al.
Publicado: (2023)

Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC
por: Zhang, Yujuan, et al.
Publicado: (2021)

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
por: Tan, Qiaoyun, et al.
Publicado: (2020)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

The clinical significance of RET gene fusion among Chinese patients with lung cancer
por: Xing, Puyuan, et al.
Publicado: (2020)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

The complete chloroplast genome sequence of Anogeissus acuminata (combretaceae)
por: Yu, Jiaojun, et al.
Publicado: (2020)

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
por: Lou, Ning, et al.
Publicado: (2023)

Fungal biomarker discovery by integration of classifiers
por: Saraiva, João Pedro, et al.
Publicado: (2017)

Role of aneuploid circulating tumor cells and CD31(+) circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC
por: Zhang, Tongmei, et al.
Publicado: (2021)

Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer
por: Yang, Yuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7rqtumlh0bfp2a7fp25s4dejl6